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Background. Diastolic dysfunction is common among dialysis patients and is associated with increased morbidity and mortality.
Novel echocardiographic speckle tracking strain analysis permits accurate assessment of left ventricular diastolic function,
independent of loading conditions and taking all myocardial segments into account. The aim of the study was to evaluate the
prevalence of diastolic dysfunction in chronic dialysis patients using this novel technique, and to identify its determinants among
clinical and echocardiographic variables. Methods. Patients currently enrolled in the ICD2 study protocol were included for this
analysis. Next to conventional echo measurements diastolic function was also assessed by global diastolic strain rate during
isovolumicrelaxation(SRIVR).Results.Atotalof77patientswereincluded(age67±8years,74%male).WhendeﬁnedasE/SRIVR
≥ 236, the prevalence of diastolic dysfunction was higher compared to more conventional measurements (48% versus 39%). Left
ventricular mass (OR 1.02, 95% CI 1.00–1.04, P = 0.014) and pulse wave velocity (OR 1.34, 95% CI 1.07–1.68, P = 0.01) were
independent determinants of diastolic dysfunction. Conclusion. Diastolic dysfunction is highly prevalent among dialysis patients
and might be underestimated using conventional measurements. Left ventricular mass and pulse wave velocity were the only
determinants of diastolic dysfunction in these patients.
1.Introduction
In dialysis patients, both cardiovascular and noncardio-
vascular mortality are signiﬁcantly increased as compared
to the general population [1]. In particular, cardiovascular
mortality contributes to ∼40% of all-cause mortality in
these patients, mainly due to sudden cardiac death [2].
Several parameters, such as left ventricular hypertrophy
(LVH) and left ventricular (LV) systolic dysfunction, have
beenidentiﬁedasindependentpredictorsof(cardiovascular)
outcome in dialysis patients. Next to that signiﬁcant diastolic
heart dysfunction, as assessed by tissue Doppler imag-
ing (TDI), has also demonstrated signiﬁcant incremental
prognostic value for all-cause mortality and cardiovascular
death [3]. Similar to the general population, diastolic heart
failure in dialysis patients often exists without the presence
of signiﬁcant systolic heart failure [4, 5]. Therefore, accurate
evaluation of LV diastolic dysfunction is crucial in the man-
agement and risk stratiﬁcation of dialysis patients, especially
in those with preserved ejection fraction. Particularly, LV
diastolic function and its determinants might represent an
important target for therapeutic options aimed at improving2 International Journal of Nephrology
the abysmal prognosis of this group of dialysis patients with
preserved ejection fraction.
Recently, LV global diastolic strain rate (SR) measure-
ment by 2D echocardiography speckle-tracking analysis was
demonstrated to be superior to the mitral annulus velocities
measuredbyTDI,fortheassessmentofLVdiastolicfunction,
especially in patients with relatively preserved LV ejection
fraction (EF) or with LV regional wall motion abnormalities.
In particular, mitral early diastolic velocity (E)/SR ratio
during LV isovolumetric relaxation (IVR) period showed to
be highly correlated with the invasive measure of pulmonary
capillary wedge pressure, and a cut-oﬀ value of 236 was able
toidentifypatientswithelevatedLVﬁllingpressurewithhigh
sensitivity and speciﬁcity [6].
The objective of this study was therefore to assess the
prevalence of signiﬁcant LV diastolic dysfunction using this
novel echocardiographic technique in a group of dialysis
patients with preserved LV systolic function. Furthermore,
possible determinants of LV diastolic dysfunction, among
several clinical and echocardiographic variables, were iden-
tiﬁed.
2. Methods
2.1. Patient Population and Protocol. All patients currently
enrolled in the ICD2 study (ISRCTN20479861) were
included in the current analysis. The rationale and protocol
of this study have been previously reported [7]. Brieﬂy, this
study evaluates the eﬀect of prophylactic implantable car-
dioverter deﬁbrillator (ICD) in chronic dialysis patients (age
55–80 years). Patients meeting current ICD implantation
criteria [8] and patients with severe comorbidities resulting
in a life expectancy of less than one year are not considered
for inclusion in the ICD2 study. The ICD2 study protocol
has been approved by the local ethics committee, and all
participating patients provided written informed consent.
All included patients underwent an extensive screening
evaluation before randomization to the treatment or control
armofthestudy.Inparticular,patientsonhemodialysiswere
evaluated on the day prior to a dialysis session. Information
was obtained on medical history and medication use.
A physical examination was performed, and EDTA and
heparinized blood samples were collected. Transthoracic
echocardiography was performed, including conventional
and advanced measures of LV diastolic function. Finally,
vascular stiﬀness was assessed by applanation tonometry.
2.2. Echocardiographic Evaluation. All patients were exam-
ined in the left lateral decubitus position with a commer-
cially available ultrasound transducer and equipment (M3s
probe, Vivid 7, GE Vingmed, Horton, Norway). The images
were digitally stored for oﬀ-line analysis (EchoPAC version
110.0.0, GE Vingmed, Horten, Norway).
According to standard techniques, a complete 2D, color,
pulse- and continuous-wave Doppler echocardiogram was
performed.UsingSimpson’sbiplanemethod[9],LVvolumes
and ejection fraction were assessed from apical 2- and
4-chamber views. LV mass was calculated by Devereux’s
formula using the M-mode of the parasternal long axis view,
and indexed to body surface area [9]. Relative wall thickness
(RWT) was calculated by the formula (2 × posterior wall
thickness in diastole)/LV internal dimension in diastole [9].
As recommended by the American Society of Echocar-
diography, maximal left atrial (LA) volume was calculated
using the ellipsoid model and indexed to body surface area
[9].
Several conventional parameters of LV diastolic function
were assessed. Transmitral E-wave velocity, E-wave deceler-
ation time (DT), and late diastolic wave (A)v e l o c i t yw e r e
measured applying pulse-wave Doppler (sample volume =
2mm) at the tip of the mitral leaﬂets in the 4-chamber view.
Furthermore, TDI was recorded with high frame rate (≥100
frames/second) from the apical 4-chamber view to assess
myocardial velocities. Peak annular early diastolic velocity
(E ) was measured in 2 annular LV segments (septal and
lateral) and averaged to calculate the mean early diastolic
velocity.TheratioE/E  wascalculated,asavalidatedestimate
ofLVﬁllingpressure,andsigniﬁcantLVdiastolicdysfunction
was deﬁned as E/E  ≥ 15.0[ 10, 11].
Advanced measures of LV diastolic function were
obtained by 2D speckle tracking SR analysis. This imaging
technique allows for the assessment of LV myocardial
deformation by tracking natural acoustic markers (speckles)
in a frame-to-frame basis within the cardiac cycle. The
speckles are visible in the standard gray-scale 2D images and
are equally distributed within the myocardium. Strain rate
during isovolumic relaxation period (SRIVR) was measured
as previously described [6, 12]. Brieﬂy, the endocardial
border was manually traced on LV apical 4-, 2-, and
3-chamber views and the region-of-interest width was
adjusted to include the entire myocardium. The images were
optimized in order to obtain the highest possible frame rate.




E/SRIVR ≥ 236 was used to identify patients with signiﬁcant
LV diastolic dysfunction [6].
2.3. Assessment of Vascular Stiﬀness. Vascular stiﬀness was
assessed noninvasively with applanation tonometry using a
SphygmoCor system (SphygomoCor, Atcor Medical, Sydney,
Australia). All measurements were performed in a quiet,
temperature-controlled clinical research laboratory. Mea-
surements were performed following a 10-minute rest in
supine position, after a state of constant heart rate and blood
pressure was reached.
The aortic pulse wave velocity (PWV) was deﬁned as the
distance traveled by the pulse wave between 2 recording sites,
divided by the passage time. Using sequential tonometry
with simultaneous electrographic gating, pulse waves were
recodedatthecommoncarotidarteryandthefemoralartery.
Following the measurements, the system software calculated
the PWV. This semiautomatic method to assess PWV has
been previously validated [13].International Journal of Nephrology 3
Figure 1: Evaluation of peak strain rate during left ventricular isovolumetric relaxation period SRIVR from the apical 4-chamber view. First,
a region of interest which includes the entire left ventricular wall is obtained (left-upper panel). The software consequently displays the
changes in longitudinal strain rate over the cardiac cycle (white dotted line). Left ventricular isovolumetric relaxation occurs in diastole,
starting immediately after closure of the aortic valve and terminating with the beginning of the diastolic early (E) wave. The peak strain rate
value during the isovolumetric relaxation period (SRIVR) is consequently measured (indicated by the white arrow). The green dotted line
indicates the timing of the aortic valve closure (AVC).
2.4. Statistical Analysis. When normally distributed (as
assessed by the Kolmogorv-Smirnov test), continuous
variables are expressed as mean ± SD and as median (25th
and 75th percentiles Q1, Q3) when nonnormally distributed.
Continuous data were compared using unpaired t-test when
normally distributed and using the Mann-Whitney U-test
when non-normally distributed. Categorical data are
expressed asfrequenciesand percentagesand werecompared
using χ2 test. Correlation between E/SRIVR and baseline
parameters was assessed using Spearsmans’ rank correlation
coeﬃcient. Multiple logistic regression analysis was per-
formed in order to establish the relationship between dif-
ferent parameters and the presence of LV diastolic dys-
function. For all tests, a P value < 0.05 was considered sta-




included in this analysis. Eight patients were excluded due to
image quality not suﬃcient for strain analysis, and 4 patients
were excluded since PWV assessment was not feasible.
Baseline clinical characteristics of the remaining 77 patients
aresummarizedinTable 1.Meanageoftheincludedpatients
was 67.2 ± 7.8 years. Patients were predominantly male
(74%), and the majority of patients were on hemodialysis
(the remaining patients were on peritoneal dialysis) with an
averagedialysisvintageofapproximately27months(median
16 months).
In these patients, echocardiography (Table 2)r e v e a l e da
relatively preserved LV size and EF, but a signiﬁcant increase
of LV mass. Average E/E  was 14.9±6.3, and an E/E  ≥ 15.0,
as index of signiﬁcant LV dysfunction, was documented in
30 (39%) patients. However using more advanced measures
of LV diastolic function, the prevalence of signiﬁcant LV
diastolic dysfunction was higher: a total of 37 (48%) patients
showed an E/SRIVR ≥ 236.
3.1. Comparison of Patients with and without Signiﬁcant LV
Diastolic Dysfunction. Clinical characteristics for patients
with (E/SRIVR ≥ 236) and without signiﬁcant LV diastolic
dysfunction (E/SRIVR < 236) are summarized in Table 1.
T h e s eg r o u p sw e r ec o m p a r a b l ew i t hr e g a r dt oa g ea n d
gender, but the prevalence of hypertension (97% versus
77%, P<0.05) and diabetes (43% versus 20%, P<0.05)
was higher in patients with LV diastolic dysfunction. These
patients were also on hemodialysis more often (73% versus
47.5%, P<0.05). Diﬀerences in dialysis vintage and history
of myocardial infarction did not reach statistical signiﬁcance.
These groups showed also signiﬁcant diﬀerences in
echocardiographic characteristics (Table 2). LV and LA vol-
umes were signiﬁcantly larger in patients with LV diastolic
dysfunction, and LV mass index (LVMI) was signiﬁcantly
higher (148 ± 48g/m2 versus 111 ± 34g/m2). Vascular
stiﬀness was also signiﬁcantly increased in patients with
diastolic dysfunction, resulting in an increased PWV as
compared to patients without LV diastolic dysfunction
(12.3 ± 3.2m/sversus9.6 ± 2.8m/s,P<0.05).
3.2. Determinants of LV Diastolic Dysfunction. Correlation
analysis revealed a signiﬁcant positive relationship between
LVMI and E/SRIVR andbetweenPWVandE/SRIVR (r = 0.43,
P = 0.001 and r = 0.31, P = 0.007, resp.). In addition,
in order to identify potential determinants of LV diastolic
dysfunction, logistic uni- and multivariate regression anal-
yses were performed (Table 3). At the univariate analysis,
hemodialysis (OR 2.98, 95% CI 1.15–7.75, P = 0.025),
hypertension (OR 10.45, 95% CI 1.26–87.16, P = 0.003),
diabetes mellitus (OR 3.05, 95% CI 1.11–8.38, P = 0.031),
PWV (OR 1.28, 95% CI 1.08–1.50, P = 0.004), RWT (OR
1.04, 95% CI 1.01–1.08, P = 0.022), and LVMI (OR 1.022,4 International Journal of Nephrology
Table 1: Baseline clinical characteristics of the total patient population and divided according to the presence (E/SRIVR ≥ 236) or not
(E/SRIVR < 236) of signiﬁcant left ventricular diastolic dysfunction.
All patients (n = 77) E/SRIVR < 236 (n = 40) E/SRIVR ≥ 236 (n = 37)
Age (yrs.) 67.2 ±7.86 6 .9 ± 8.36 7 .7 ±7.4
Male gender 57 (74.0%) 28 (70.0%) 29 (78.4%)
Hemodialysis 46 (59.7%) 19 (47.5%) 27 (73.0%)∗
Dialysis vintage (months) 16 [9,34] 12 [8,26] 21 [10,52]
NYHA class
I 52 (68.5%) 30 (75.0%) 22 (59.5%)
II/III 25 (31.5%) 10 (25.0%) 15 (40.5%)
Hypertension 67 (87.0%) 31 (77.5%) 36 (97.3%)∗
BSA 1.93 ±0.21 1.93 ±0.20 1.92 ±0.21
Diabetes mellitus 24 (31.2%) 8 (20.0%) 16 (43.3%)∗
Myocardial infarction 21 (27.3%) 9 (22.5%) 12 (32.4%)
Hemoglobin (mmoL/L) 7.6 ±0.87 .6 ±0.77 .7 ±0.9
Creatinine (μmol/L) 649 ±203 650 ±230 648 ±174
Calcium (mmoL/L) 2.37 ±0.17 2.4 ±0.19 2.4 ±0.17
Phosphate (mmoL/L) 1.49 ±0.31 1.5 ±0.31 .5 ±0.3
β-blocker 43 (55.8%) 22 (55.0%) 21 (56.8%)
ACEI/ARB 41 (53.2%) 22 (55.0%) 19 (51.4%)
Statins 55 (71.4%) 28 (70.0%) 27 (72.3%)
PWV (m/s) 10.9 ±3.39 .6 ±2.81 2 .3 ±3.3∗
∗P<0.05 between patients with E/SRIVR < 236 and patients with E/SRIVR ≥ 236.
ACEI/ARB: angiotensin-converting enzyme inhibitors or receptor blockers; BSA: body surface area; NYHA: New York Heart Association; PWV: pulse wave
velocity.
Table 2: Echocardiographic characteristics of the total patient population and divided according to the presence (E/SRIVR ≥ 236) or not
(E/SRIVR < 236) of signiﬁcant left ventricular diastolic dysfunction.
All patients (n = 77) E/SRIVR < 236 (n = 40) E/SRIVR ≥ 236 (n = 37)
LVEDV (mL) 107 ±40 97 ±38 118 ±42∗
LVESV (mL) 52 ±26 46 ±22 60 ±28∗
LVEF (%) 52%± 7 54%± 6 51%± 8
LA volume (mL/m2)2 6 .8 ±12.22 2 .7 ±10.93 1 .3 ±12.1∗
LVMI (g/m2) 129 ±45 111 ± 34 148 ±48∗
RWT 0.53 ±0.15 0.49 ±0.13 0.57 ±0.15∗
E( c m / s ) 0 .75 ±0.25 0.71 ±0.23 0.77 ±0.26
E/A ratio 0.88 ±0.33 0.86 ±0.33 0.90 ±0.34
DT (ms) 261 ±81 267 ± 78 255 ±84
E/E  ratio 14.9 ±6.31 2 .1 ± 4.81 7 .9 ±6.3∗
SRIVR 203 [145,353] 149 [107,189] 354 [304,457]∗
∗P<0.05 between patients with E/SRIVR < 236 and patients with E/SRIVR ≥ 236.
A: late diastolic transmitral ﬂow velocity; DT: deceleration time; E: early diastolic transmitral inﬂor velocity; E : peak annular early diastolic velocity; LA: left
atrial; LVEDV: left ventricular end diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end systolic volume; LVMI: left ventricular
mass index; RWT: relative wall thickness; SRIVR: strain rate during isovolumic relaxation.
95% CI 1.01–1.04, P = 0.001) were signiﬁcant predictors for
the presence of LV diastolic dysfunction. The multivariate
model included all parameters with a P value < 0.20 in
the univariate analysis and demonstrated that PWV (OR
1.34, 95% CI 1.07–1.68, P = 0.015) and LVMI (OR 1.02,
95% CI 1.00–1.04, P = 0.014) were the only independent
determinants of signiﬁcant LV diastolic dysfunction.
4. Discussion
The key ﬁndings of this study can be summarized as follows:
using LV global diastolic SR measurement, the prevalence of
LV diastolic dysfunction in dialysis patients with preserved
LVEF was approximately 50%. Using conventional echocar-
diographic methods, this prevalence was lower, indicatingInternational Journal of Nephrology 5
Table 3: Uni- and multivariate logistic regression analysis to predict the presence of LV diastolic dysfunction (deﬁned as E/SRIVR ≥ 236).
Univariate Multivariate
HR 95% CI P-value HR 95% CI P value
Age 1.013 0.96–1.07 0.65
Male gender 1.56 0.55–4.37 0.40
Hemodialysis 2.98 1.15–7.75 0.025 2.64 0.75–9.21 0.13
Dialysis vintage
(months) 1.016 1.00–1.04 0.085 1.013 0.99–1.03 0.22
Hypertension 10.45 1.25–87.16 0.03 4.91 0.46–51.83 0.19
DM 3.05 1.11–8.38 0.031 2.40 0.57–10.08 0.23
MI 1.65 0.60–4.55 0.33
LVMI 1.022 1.01–1.04 0.001 1.02 1.00–1.04 0.014
RWT 1.04 1.01–1.08 0.022 0.99 0.94–1.04 0.652
PWV 1.35 1.13–1.62 0.001 1.34 1.07–1.68 0.010
DM: diabetes mellitus; LVMI: left ventricular mass index; MI: myocardial infarction; PWV: pulse wave velocity; RWT: relative wall thickness.
a possible underestimation when applying these techniques.
In addition, LVMI and PWV were the only independent
determinants of LV diastolic dysfunction in this patient
group.
4.1. Cardiovascular Mortality in Dialysis Patients. Cardio-
vascular disease largely contributes to the poor outcome in
dialysis patients, and sudden cardiac death especially has
been put forward as an important cause of mortality in
this patient group. It has been reported that sudden cardiac
death accounts for almost 60% of cardiovascular mortality
and is the cause of death in approximately 25% of dialysis
patients [2, 14, 15]. The mechanisms underlying sudden
cardiac death in this patient group are complex and not
yet completely understood. Next to the traditional cardio-
vascular risk factors, such as ischaemic heart disease [16],
many other factors have also been reported to be associated
withcardiovasculardeathindialysispatients,includingLVH,
abnormalities in myocardial ultrastructure and function,
interstitial ﬁbrosis, and sympathetic overactivity [14, 17].
Recently, it has been demonstrated that LV diastolic
dysfunction provides independent and additional prognostic
value for long-term mortality and cardiovascular death in
patients with end-stage renal disease, above and beyond that
of LVM and LVEF [3]. Therefore, identifying patients with
LV diastolic dysfunction might help in developing treatment
strategies and in selecting patients most likely to beneﬁt
from these strategies. Given the possible underestimation of
diastolic dysfunction using more conventional echocardio-
graphic measurements, this novel technique would probably
allow for more optimal patient selection for these treatment
strategies.Finally,preventingthedevelopmentofLVdiastolic
dysfunction might also improve outcome and reduce the
incidence of cardiovascular death in dialysis patients.
4.2. Assessment of LV Diastolic Function. Recent studies
evaluating LV diastolic function in dialysis patients used
the ratio of early mitral diastolic velocity to early diastolic
velocity (E/E  ratio) [3, 18]. Although it is a clinically useful
method to assess LV diastolic function, the measurement
of E  has a number of limitations which can aﬀect its
accuracy. Firstly, this approach is an approximation of LV
global function, assuming that a single or multiple site(s)
represent global LV relaxation. However, it is known that
even in patients without segmental dysfunction, LV regional
diﬀerences exist. Particularly in dialysis patients, signiﬁcant
LV diastolic dyssynchrony has been described to be often
present [19].
Another important limitation of this approach is the
potential eﬀect of LA pressure. Since E  occurs during the
early phase of LV ﬁlling, not only LV relaxation, but also
LA pressure has an important impact on its value [20, 21].
This limitation is particularly important in dialysis patients,
given the high prevalence of hypertension and chronic ﬂuid
overload in these patients.
Conversely,globalLVdiastolicSRmightovercomeallthe
abovementioned limitations. This measurement reﬂects in
fact the performance of all LV segments, it is load indepen-
dent and accounts for the initial LV size. Furthermore, when
measured during the IVR period (when the mitral valve is
still closed) and expressed in a ratio with the transmitral
E wave, it takes into account the mean LA pressure [6].
Recently, Wang et al. demonstrated that E/SRIVR can be
used to estimate LV ﬁlling pressures, with higher sensitivity
and speciﬁcity as compared to E/E , particularly in patients
with preserved LVEF and in those with regional dysfunction
[6]. However, the measurement of global SRIVR requires the
presence of adequate apical views, and therefore it is not
feasible in patients with suboptimal apical windows. In the
present study, this measurement was feasible in 92% of the
patients.
4.3. Determinants of LV Diastolic Dysfunction. Among the
clinical and echocardiographic variables assessed in this
study,LVMIandaorticstiﬀness,assessedwithPWV,werethe
only independent predictors for the presence of LV diastolic
dysfunction. Therapies preventing further progression of
LVMI and/or aortic stiﬀness might therefore prevent and/or
limit the development of LV diastolic dysfunction.6 International Journal of Nephrology
Severaltherapeuticstrategieshaveshownbeneﬁcialeﬀect
on LVH (limiting progression or even inducing regression),
including angiotensin-converting enzyme inhibitor (ACEi)
[22], angiotensin reuptake blocker (ARB) therapy, and in-
creasing dialysis frequency (nocturnal) [23, 24]. However,
their use has not been (yet) associated with a statistically
signiﬁcant reduction in fatal and nonfatal cardiovascular
events.
Arterial stiﬀening occurs normally with aging and also
correlates with the prevalence of atherosclerosis [25]. For
patients with end-stage renal disease, additional mechanisms
are probably responsible for increased arterial stiﬀening,
namely, the extensive calciﬁcation of the vessel wall, resulting
in both heavily calciﬁed atherosclerotic plaques and calciﬁ-
cation of the muscular media layer of the vessel wall [26].
Therapeutic strategies aiming at reducing progression of
vascular calciﬁcation could therefore prevent further pro-
gression of arterial stiﬀening and thereby the development
of LV diastolic dysfunction. Current strategies that are being
investigated in this regard focus on inhibiting the eﬀects
of secondary hyperparathyroidism with phosphate binders
and calcimimetics [27, 28]. Vascular stiﬀening may also be
improved using antihypertensive medication (ACEi, ARB,
B blockers) [29]; however, due the small sample sizes and
the selected patient groups in which the studies have been
conducted, these results cannot be generalized to dialysis
patients.
Advanced glycation end product cross-link breakers also
have emerged as a potential therapeutic strategy, and it has
been demonstrated that cross-link breakers improve arterial
compliance, PWV, and pulse pressure in a selected group of
patients [30].
4.4. Study Limitations. Given the lack of invasive measure-
ments, this study does not allow for deﬁnitive conclusions
regarding the accuracy of E/SRIVR for the identiﬁcation of
signiﬁcant LV diastolic dysfunction. It should be noted how-
ever that Wang et al. recently demonstrated in a validation
study that E/SRIVR has signiﬁcantly higher speciﬁcity and
sensitivity as compared to more conventional measurements
for the estimate of LV ﬁlling pressures. Furthermore, this
study was primarily designed to assess and describe the
prevalence of LV diastolic dysfunction according to an
advanced echocardiographic measurement and moreover to
establish its clinical determinants, rather than to compare
it to more conventional echocardiographic techniques. The
patients used in this analysis are patients with a life expec-
tation of at least 1 year, given the nature of the ICD2 study
protocol. Therefore the “sickest” patients are being excluded,
and therefore the prevalence of LV diastolic dysfunction
might be underestimated. Furthermore, due to the relatively
low number of patients and relatively short period of follow-
up in the ICD2 study, long-term outcome data could not
be included. Before the true additional value of this novel
technique can be established, also long-term outcome data
should be analyzed in future studies.
5. Conclusion
In dialysis patients with preserved LVEF, the prevalence of
LV diastolic dysfunction assessed by global LV SR is relatively
high and might be underestimated when using conventional
echocardiographictechniques.Inthesepatients,LVmassand
PWV are independent predictors of LV diastolic dysfunction
and could serve as possible therapeutic targets.
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